We determined whether assessment of the immunogenicity of individual donor-recipient HLA mismatches based on differences in their amino-acid sequence and physiochemical properties predicts clinical outcome following haematopoietic SCT (HSCT). We examined patients transplanted with 9/10 single HLA class I-mismatched grafts (n = 171) and 10/10 HLA-A-, -B-, -C-, -DRB1-and -DQB1-matched grafts (n = 168). A computer algorithm was used to determine the physiochemical disparity (electrostatic mismatch score (EMS) and hydrophobic mismatch score (HMS)) of mismatched HLA class I specificities in the graft-versus-host direction. Patients transplanted with HLA-mismatched grafts with high EMS/HMS had increased incidence of ⩾ grade II acute GVHD (aGVHD) compared with patients transplanted with low EMS/HMS grafts; patients transplanted with low and medium EMS/HMS grafts had similar incidence of aGVHD to patients transplanted with 10/10 HLA-matched grafts. Mortality was higher following single HLAmismatched HSCT but was not correlated with HLA physiochemical disparity. Assessment of donor-recipient HLA incompatibility based on physiochemical HLA disparity may enable better selection of HLA-mismatched donors in HSCT.
INTRODUCTION
Haematopoietic SCT (HSCT) represents a potentially curative treatment option for life-threatening haematological disorders such as leukaemias and bone marrow failure syndromes. However, the diversity of the human MHC system and the limited number of stem cell donors necessitates the selection of HSCT donor-recipient pairs who are not fully HLA matched. Incompletely HLA-matched grafts are associated with increased morbidity, including acute GVHD (aGHVD), and mortality following transplantation. 1 The ability, therefore, to select HLA-mismatched donor grafts that are of low immunogenicity for a given recipient is of great interest in HSCT.
It has been suggested that alloimmune responses in the context of transplantation may be predicted based on information derived from the amino-acid (AA) sequences of HLA molecules. 2 However, previously developed tools for assessing HLA immunogenicity were shown to be unsuitable for predicting cellular alloreactivity. 3, 4 We have recently proposed an algorithm to assess HLA compatibility in HSCT based on the number, position and nature of AA polymorphisms in the α1/α2 domains of mismatched donor-recipient HLA class I molecules. 5 Although this proved useful in predicting donor cytotoxic T lymphocyte precursor reactivity against mismatched recipient HLA molecules in vitro, the algorithm was not predictive of clinical outcomes, such as aGVHD and mortality, following single HLA mismatch HSCT. 6 In the context of solid-organ transplantation, the immunogenicity of HLA class I and class II alloantigens relates not only to the number of AA polymorphisms between mismatched HLA molecules but also to their physiochemical differences. 7, 8 In this report, we describe an analysis of fully matched and single HLA class I-mismatched grafts and show that the physiochemical disparity between mismatched HLA alloantigens is predictive of the risk of developing aGVHD following HSCT.
MATERIALS AND METHODS

Donor-recipient pairs
The study cohort consisted of 171 consecutive patients who received a 9/10 single HLA-A (n = 60), HLA-B (n = 27) or HLA-C (n = 84) mismatched HSCT graft between 1988 and 2008 in three centres in the Netherlands (Erasmus MC Rotterdam, University Medical Centre Utrecht and Leiden University Medical Centre). As controls we selected 168 10/10 HLA-A, -B, -C, -DRB1 and -DQB1 allele-matched donor-recipient pairs, matched for HSCT year, donor type, patient age and disease diagnosis to the single HLA class I-mismatched cohort (total cohort: n = 339). The study population included pediatric (n = 112) and adult patients (n = 227) with malignant (n = 296) and nonmalignant (n = 43) diseases. Donors originated from national or international volunteer bone marrow donor registries, and 20 were family donors. Clinical patient information was made available by the HOVON Data Centre through the European group for Blood and Marrow Transplantation patient database.
HLA genotyping, AA sequencing and physicochemical properties
All HSCT donors and patients were HLA typed at allele level for HLA-A, -B, -C, -DRB1 and -DQB1, as described previously. 9 The AA sequence comparisons between mismatched HLA class I specificities at the graft-versus-host direction were performed using a previously described computer program 7 (available on request). The program allows identification of the position and nature of all disparate AAs in the entire 1 Department of Surgery, University of Cambridge, and NIHR Cambridge Biomedical Research Centre, Cambridge, UK; α1 and α2 domains. For the purposes of this study, focussing on cellular allorecognition, the program was adjusted to enable separate consideration of residues that are important in TCR recognition and/or peptide binding. Accordingly, AA at positions 49-85 and 137-180 in the α-helices were considered important for TCR contact and residues at positions 3-13, 21-29, 31-38, 45-48, 93-104, 108-119, 121-127 and 132-136 in the β-sheets were considered important for peptide binding. [10] [11] [12] [13] Donorrecipient AA mismatches at each sequence position were scored according to their hydrophobic (using the Hopp-Woods hydrophobicity scale 14 ) and isoelectric point disparities. For each donor-recipient HLA class I mismatch combination, the individual AA physiochemical disparity scores were summed to give a total hydrophobicity mismatch score (HMS) and a total electrostatic mismatch score (EMS). 7 End points and competing risks Primary end point for the HSCT analysis was incidence of ⩾ grade II aGVHD. Peak severity of aGVHD after HSCT defined according to grade (no, I, II, III or IV) was available for 317 patients. Patients were censored at date of donor leukocyte infusion, relapse or second HSCT within 100 days after HSCT and at 100 days after HSCT. Death without ⩾ grade II aGVHD within 100 days after HSCT was treated as a competing risk. Secondary outcomes in the HSCT analysis were incidence of relapse and mortality. Patients were censored at date of donor leukocyte infusion or second HSCT and those who survived were censored at time of last contact. For analysis of relapse, death without relapse was defined as competing risk.
Statistical analysis
For the single 9/10 HLA class I-mismatched grafts, the number of AA differences, EMS and HMS variables were divided into three groups based on their distribution (overall, EMS ranged from 0 to 58.9 whereas EMS for α-helices and β-sheets ranged from 0 to 47.3 and from 0 to 18.2, respectively; similarly, HMS ranged from 0 to 66.2 whereas HMS for α-helices and β-sheets ranged from 0 to 45.5 and from 0 to 20.3, respectively). The lowest tertile was set as reference category. Tertiles were used to ensure objectivity and even-sized categories.
Association between EMS/HMS of single 9/10 HLA class I mismatches and HSCT outcome was investigated relative to 10/10 HLA-matched HSCT. Differences in patient, donor and HSCT characteristics between low, medium and high EMS/HMS were examined with Pearson's χ 2 test or Fishers' exact test for discrete variables and Kruskal-Wallis test for continuous variables. Hazard ratios, 95% confidence intervals and P-values were obtained using the proportional hazards model for the subdistribution of competing risks of Abbreviations: aGVHD = acute GVHD; CI = confidence interval; EMS = electrostatic mismatch score; HR = hazard ratio; HSCT = haematopoietic SCT. a Information on aGVHD was not available for 22 patients (13 had single 9/10 HLA-mismatched grafts and 9 had 10/10 HLA-matched grafts). b Only patients with malignant diseases were considered (N = 296). Abbreviations: aGVHD = acute GVHD; ATG = antithymocyte globulin; CI = confidence interval; EMS = electrostatic mismatch score; HR = hazard ratio; HSCT = haematopoietic SCT. P-values in bold denote statistical significance.
Physiochemical 15 to quantify the association between EMS/HMS and cumulative incidence of ⩾ grade II aGVHD, relapse and mortality.
Patient, donor and HSCT characteristics that were associated with EMS or HMS and HSCT end points were considered as potential confounding variables in our data set. They were evaluated for each end point separately and identified as confounding variables when including them in the model (one by one); the crude association (β estimate) changed by 410%.
For aGVHD, relapse and mortality models, the following variables were considered: HSCT centre (Erasmus MC, University Medical Centre Utrecht or Leiden University Medical Centre), mismatched locus (HLA-A, -B or -C), HSCT year (continuous), patient age at HSCT (continuous), donor age at HSCT (continuous), cyclosporine use (y/n), campath use (y/n), T-cell depletion of the graft (y/n), TBI part of the conditioning (y/n) and conditioning type (myeloablative/reduced intensity). All identified confounding variables, and variables considered clinically important, were included in the multivariate models. Two-sided P-values of ⩽ 0.050 were considered statistically significant. Statistical analysis was performed using SPSS 19.0 for Windows (IBM Corp., Armonk, NY, USA) and the CMPRSK package in R (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
We have analysed clinical HSCT outcomes in a large cohort of fully HLA-matched and single HLA class I-mismatched grafts (n = 339).
There was no association between the number of AA mismatches in single HLA-A-, -B-or -C-mismatched grafts and the incidence of aGVHD, relapse or mortality (data not shown). Similarly, separate consideration of AA mismatches in sequence positions important for TCR recognition or peptide binding showed no association with primary or secondary outcomes. However, donor-recipient pairs with a single HLA mismatch and a high EMS showed a statistically significant increase in the cumulative incidence of ⩾ grade II aGVHD compared with pairs with a single HLA mismatch and low EMS (hazard ratio 2.82, 95% confidence interval 1.22-6.53, P = 0.016). Of patients transplanted with 9/10 single HLA-mismatched grafts, those with low and medium EMS had similar risk of aGVHD compared with patients transplanted with 10/10 HLA-matched grafts (Tables 1a and b and Figure 1a) . On multivariable analysis, only high EMS and recipient age (pediatric versus adult) had an independent effect on risk of ⩾ grade II aGVHD (Table 1b) . In this study cohort, the incidence of severe aGVHD (⩾ grade III aGVHD) was relatively low (Supplementary Figure 1) ; although there was a trend towards increased risk of ⩾ grade III aGVHD in patients with single HLAmismatched grafts and high EMS, this did not reach statistical significance (Supplementary Table 1 Figure 2) . Information on aGVHD was not available for 22 patients (total cohort n = 317). Only patients with malignant diseases were considered for analysis of relapse (n = 296).
Physiochemical HLA disparity and acute GVHD V Kosmoliaptsis et al
Patients transplanted with a 10/10 HLA-matched graft had superior survival compared with patients transplanted with a 9/10 single HLA-mismatched graft but, within the latter group of patients, no difference was observed in cumulative mortality between groups with different levels (low, medium and high) of EMS (Tables 1a and b and Figure 1c) . Finally, the cumulative incidence of disease relapse was similar for patients transplanted with HLA-matched and HLA-mismatched grafts, independent of physiochemical disparity scores (Tables 1a and b and Figure 1b) . Patients with low, medium and high EMS scores were similar with respect to all patient, donor and HSCT characteristics examined, with the exception of the frequency of HLA-A, -B and -C mismatches (Table 2) . However, the mismatched HLA locus had no effect on HSCT outcomes. Moreover, we observed no difference in HLA-DPB1 mismatches between donor-recipient pairs with high, medium and low EMS.
When the impact of HMS was considered, similar results were obtained (aGVHD hazard ratio 2.96, 95% confidence interval 1.09-8.05, P = 0.033 for patients with high EMS grafts; Supplementary  Figures 1 and 2 ) with no independent effect of HMS over EMS (EMS and HMS values were highly correlated). Similarly, when the physiochemical disparity of single HLA-mismatched grafts was calculated based on AA differences located in TCR or peptide contact positions, the relationship with incidence of aGVHD remained significant but the strength of the association did not improve (data not shown).
DISCUSSION
In the absence of a fully HLA-matched graft, selection of a suitable donor for a given recipient represents a major challenge in HSCT. In this pilot study, we have shown that HSCT recipients of single Table 2 . Characteristics of patients transplanted with a single HLA class I-mismatched graft Low EMS, n = 60 Medium EMS, n = 54 High EMS, n = 57 P-value Total, n = 171 Controls, n = 168 P-value Abbreviations: ATG = antithymocyte globulin; EMS = electrostatic mismatch score; HSCT = haematopoietic SCT; MDS = myelodysplastic syndrome; MPS = myeloproliferative syndrome; TCD = T-cell depletion. Analyses with hydrophobic mismatch score (HMS) showed similar results (data not shown). P-values in bold denote statistical significance.
Physiochemical HLA disparity and acute GVHD V Kosmoliaptsis et al HLA-mismatched grafts with high physiochemical disparity (EMS) were more likely to have aGVHD compared with recipients of grafts with low EMS; the risk of aGVHD for patients transplanted with low and medium EMS grafts was similar to that of HSCT recipients of fully (10/10) HLA-matched grafts. This association was independent of the mismatched HLA locus (HLA-A, -B or -C) and of the number of AA polymorphisms between donor and recipient HLA and was evident when either the α-helices and β-sheets only or the entire α1/α2 domains were considered. We were not able to identify an independent effect of AA substitutions at specific peptide binding positions on the risk of aGVHD, 16, 17 although we recognise that our study may have lacked the necessary power to fully discern such an effect. The increased incidence of aGVHD observed for high EMS grafts did not translate into higher mortality rates and, in this cohort, physiochemical disparities or AA sequence differences between donor-recipient HLA were not predictive of patient mortality. This is perhaps not surprising given that mortality following HSCT is a composite outcome and to a significant extent the result of infections in an immunocompromised host. On the other hand, a larger cohort of HSCT patients may have to be analysed to better delineate this relationship.
A potential limitation of our study is the analysis of a relatively small and heterogeneous patient cohort. To avoid confounding, given than mismatching for a single HLA-DRB1 is associated with increased incidence of aGVHD and mismatching at HLA-DQB1 in the presence of mismatches at other loci (HLA-A, -B, -C or -DRB1) may have a detrimental effect on mortality, 18 all donor-recipient pairs in this analysis were matched for HLA-DRB1 and HLA-DQB1. Mismatching for HLA-DPB1 is also associated with increased risk of aGVHD. 19 Additional matching of our donor-recipient pairs for HLA-DPB1 was not possible. Only 15-20% of 10/10 HLA-matched pairs are also matched at the HLA-DPB1 locus because of weak linkage disequilibrium between HLA-DPB1 and the rest of the MHC. However, we observed no difference in HLA-DPB1 mismatches between donor-recipient pairs with high, medium and low EMS. Factors that were found to be associated with aGVHD, relapse and/or mortality were included in the multivariate model to correct for confounding. The change in the estimates was minor and therefore confounding was unlikely to have played a major role in our analysis. A major strength of our survival analysis was the utilisation of competing risk analysis in both unrelated donor search and transplantation analysis preventing overestimated estimates.
In conclusion, this report shows for the first time that high physiochemical disparity between mismatched HLA class I alloantigens correlates with increased risk of aGVHD following HSCT. Assessment of donor-recipient HLA compatibility based on physiochemical disparities may provide valuable information when fully HLA-compatible HSCT is not an option. Further studies in a larger patient cohort are needed to determine the clinical applicability of both HLA class I and class II physiochemical disparity scores in HSCT.
